Western Blot: CDT1 Antibody [NB100-2567] - Whole cell lysate from HeLa (5, 15 and 50 ug for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 ug) cells. Affinity purified rabbit anti- CDT1 antibody (NB100-2567) used ...read more
Immunohistochemistry-Paraffin: CDT1 Antibody [NB100-2567] - Human islet cell carcinoma. Antibody used at a dilution of 1:1000 (1ug/ml).
Immunohistochemistry-Paraffin: CDT1 Antibody [NB100-2567] - FFPE section of human ovarian tumor.
Immunohistochemistry-Paraffin: CDT1 Antibody [NB100-2567] - FFPE section of human metastatic lymph node.
The immunogen recognized by this antibody maps to a region between residue 500 and the C-terminus (residue 546) of human Chromatin Licensing and DNA Replication Factor 1 using the numbering given in entry NP_112190.1 (GeneID 81620).
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
This antibody can be used in Western Blot, Immunohistochemistry-Paraffin and Immunoprecipitation. Epitope exposure is recommended. Epitope exposure with citrate buffer will enhance staining. Likely to work with frozen sections The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read 1 Review rated 5 using NB100-2567 in the following application:
Based on 100% sequence identity, this antibody is predicted to react with Chimpanzee.
Alternate Names for CDT1 Antibody
chromatin licensing and DNA replication factor 1
DNA replication factor Cdt1
Double parked homolog
Double parked, Drosophila, homolog of
Geminin is a protein that inhibits DNA replication by preventing the loading of MCM complex on chromatin. Human CDT1 is a 65kDa protein that contains 546 amino acids and coimmunoprecipitates with Geminin. Inhibition of DNA replication by Geminin in cell-free cDNA replication extracts can be reversed by the addition of excess CDT1. In the normal cell cycle, CDT1 is present only in G1 and S phases, whereas Geminin is present in S and G2 phases. Wohlschlegel et al. (2000) concluded that their results suggest that Geminin inhibits inappropriate origin firing by targeting CDT1. This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animals cells produce the protein, which stimulates the animals immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.